CN1258373C - Medicine for treating lumbosacral pain and its preparing method - Google Patents
Medicine for treating lumbosacral pain and its preparing method Download PDFInfo
- Publication number
- CN1258373C CN1258373C CN 200310109939 CN200310109939A CN1258373C CN 1258373 C CN1258373 C CN 1258373C CN 200310109939 CN200310109939 CN 200310109939 CN 200310109939 A CN200310109939 A CN 200310109939A CN 1258373 C CN1258373 C CN 1258373C
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- water
- medicine
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000008035 Back Pain Diseases 0.000 title claims abstract description 63
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 6
- 241000725145 Homalomena Species 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 14
- 230000036407 pain Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 210000000713 mesentery Anatomy 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 6
- 206010018691 Granuloma Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000001624 hip Anatomy 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229930189907 rotundine Natural products 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 101000874172 Rattus norvegicus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to medicine for treating lumbosacral pain and a preparation method thereof, which belongs to the field of traditional Chinese medicine. The medicine is prepared from the following raw material by weight parts: 10 to 30 parts of epimedium herb, 10 to 30 parts of obscured homalomena rhizome, 10 to 30 parts of difengpi bark and 10 to 15 parts of twotoothed achyranthes root. The preparation method comprises: decocting the raw material in water, concentrating an extracting solution so as to obtain extract, drying and crushing the extract and adding auxiliary material to the crushed extract so as to prepare a selected preparation. The present invention has the advantages that medicinal functions and mutual synergistic effects of the raw material are utilized, and the present invention provides a pure traditional Chinese medicine preparation for treating lumbosacral pain, which has obvious effects on pain alleviation and takes effect rapidly.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of lumbosacral pain and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Lumbosacral pain is a kind of common clinical disease of the waist and sacrum pain that caused by the waist sacrum disease that multiple diseases such as lumbar vertebra hyperosteogeny, lumbar muscle strain cause, belongs to " arthromyodynia ", " lumbago " category of the traditional Chinese medical science.A little less than how considering by patient's body constitution, yang-energy, cloudy QI-insufficiency, space between skin and muscles is empty, so exopathogen is invaded, promptly after the disease, unable again getting rid of evils gone out, so that exopathogen go deep into, lingers in the muscles and bones blood vessels, QI and blood numbness hinders obstructed, muscle arteries and veins joint lose in moisten foster due to.The primary disease sickness rate is higher, but singly deposits the medicine that is used for the treatment of lumbosacral pain, particularly can quickly alleviating pain, remove the Chinese medicine of lumbosacral pain, and also do not study so far, manufacture out.
Summary of the invention:
The medicine that the purpose of this invention is to provide a kind of effective treatment lumbosacral pain, the lumbosacral pain that a variety of causes is caused all has the quickly alleviating pain effect, remedies the deficiencies in the prior art.
Another object of the present invention is the preparation method that provides this medicine.
Medicine of the present invention is made by following parts by weight of traditional Chinese medicines raw material: Herba Epimedii 10-30 part, Rhizoma Homalomenae 10-30 part, Cortex Illicii 10-30 part, Radix Achyranthis Bidentatae 10-15 part.
The parts by weight of each raw material preferable amount of medicine of the present invention are: 20 parts of Herba Epimedii, 20 parts of Rhizoma Homalomenaes, 20 parts of Cortex Illiciis, 10 parts of Radix Achyranthis Bidentataes.
Why the present invention selects Herba Epimedii, Rhizoma Homalomenae, Cortex Illicii, Radix Achyranthis Bidentatae for use is raw material, makes up to be based on:
Herba Epimedii, hot, sweet, warm.Return liver, kidney channel.Kidney-replenishing, bone and muscle strengthening, wind-damp dispelling.Be used for impotence and seminal emission, the muscles and bones flaccidity is soft, the pathogenic wind-warm arthralgia pain, and so numbness contracture is with its kidney warming sun, damp-clearing pain-relieving and be monarch.Rhizoma Homalomenae, bitter, hot, warm, return liver, kidney channel.Wind-damp dispelling, muscle reinforcing and bone strengthening.Be used for anemofrigid-damp arthralgia, chills and pain of the waist and kness, lower limb contracture numbness." book on Chinese herbal medicine justice " is said: " Rhizoma Homalomenae, modern perseverance is used for ventilation meridian, dispels the wind by numbness, quite has confirmed ".Cortex Illicii, little suffering, puckery, temperature.Return bladder, kidney channel.Expelling wind and removing dampness, promoting the circulation of QI to relieve pain.Be used for the pathogenic wind-warm arthralgia pain, lumbar muscle strain.Two medicines mutually 5, the inducing menstruation to relieve menalgia effect brings out the best in each other, and assists monarch drug to strengthen analgesic effect jointly and is ministerial drug.Radix Achyranthis Bidentatae, bitter, acid, flat.Return liver, kidney channel invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.Be used for soreness of waist and knee joint, muscles and bones is unable, dizziness due to hyperactivity of liver-YANG." medicine mirror ": " can help the twelve regular channels.Main brothers' cold-damp flaccidity syndrome and arthralgia syndrome, big muscle contracture." " Amplification on Materia Medica addendum ": " it is descending to draw all medicines ", so be adjuvant, draw the through sick institute of all medicines.All medicines share, and play the warming YANG damp eliminating altogether, the effect of inducing menstruation to relieve menalgia.
The preparation method of medicine of the present invention is:
1. earlier the Herba Epimedii of described weight proportion is decocted with water 3 times, add the water of 10 times of weight at every turn, decocted 20 minutes, collecting decoction, filtration, filtrate is evaporated to relative density and crosses 1.10-1.15 under 80 ℃, 0.06-0.08Mpa condition;
2. Rhizoma Homalomenae, Cortex Illicii, the Radix Achyranthis Bidentatae of described weight proportion decocted with water 3 times again, add the water of 8 times of weight at every turn, decocted 1 hour, collecting decoction filters, and filtrate is evaporated to relative density and crosses 1.10-1,15 under 80 ℃, 0.06-0.08Mpa condition;
3. merge Herba Epimedii and Rhizoma Homalomenae, Cortex Illicii, Radix Achyranthis Bidentatae mixes the fluid extract after the decocting and concentrating, continues to be concentrated into the relative density mistake under 80 ℃, 0.06-0.08Mpa condition.28-1.31, again under 80 ℃, 0.08Mpa condition, drying under reduced pressure; Dry thing is ground into fine powder, promptly makes medicament active composition of the present invention.
Required various conventional adjuvant when 4, adding the preparation different dosage form in prepared fine powder is made oral agents commonly used or externally used coating agent with the method for Chinese medicinal of routine, oral agents such as ball, loose, sheet, capsule.Externally used coating agent such as cream, tincture.
Good effect of the present invention is: utilized raw materials used medicinal function and synergism each other, provide a kind of analgesic effect definite, the pure Chinese medicinal preparation of rapid-action treatment lumbus sacrum pain.
Medication effect experimental example of the present invention:
1 experiment material
1.1. animal: Kunming mouse, body weight 20 ± 2g, the male and female dual-purpose (quality certification number: 10-1023); The Wistar rat, body weight 200 ± 30g, the male (quality certification number: 10-1026).Provide by Jilin University's Experimental Animal Center.
1.2. medicine and reagent: drug particles of the present invention, medicine name " lumbosacral pain ".Clinical consumption per day 0.194g/kg (be equivalent to 0.583g crude drug/kg), lot number: 20030219, provide by sky medicine Science and Technology Co., Ltd. Chemistry for Chinese Traditional Medicine chamber; Aspirin Enteric-coated Tablets, specification: the 0.3g/ sheet, lot number: 020907, Shaanxi pharmaceutical factory product; Capsules for curing waist pain (abbreviation YAOXITONG), specification: the 0.3g grain, lot number: 020601, JiLin ZiXin Pharmacy Co., Ltd; FUFANG DANSHEN DIWAN, specification: the 25mg/ grain, lot number: 20020806, Tianjin Tasly Pharmaceutical Co., Ltd; The rotundine crystallization, Yuxi, Yunnan is natural drug company limited (purity 98.7%) incomparably; The injection of morphia agent, specification: 10mg/ml, lot number: 880501 Shenyang No. 1 Pharmaceutical Factories; Pentobarbital sodium, specification: analytical pure, lot number: 840612, Shanghai chemical reagent packing factory; Carrageenin, the institute of materia medica, Shenyang; Benzylpenicillin sodium for injection, specification: 1,600,000 units/, lot number: X0211301, Huabei Pharmaceutic Co., Ltd; ZHUSHEYONG LIUSUAN LIANMEISU, 1,000,000 units/, lot number: 20020604, the big pharmaceutical factory of Dalian Metro; High molecular dextran (Dextran, MW 500,000), Sweden PharmaciaFine Chemicals AB UPPSALA, lot number: 17-0320-01.
1.3. instrument: use instrument adnexa electric heater, Bangbu radio two factories more; The TU-1800s ultraviolet-uisible spectrophotometer, the Beijing Puxi General Instrument Co., Ltd; BI-2000 medical image analysis instrument, Chengdu TME Technology Co., Ltd..
2. statistics are handled and method for expressing
Data is added and subtracted standard deviation with mean, and (x ± s) expression, statistical procedures is carried out in the t check between the employing group.
3. method and result
3.1 the influence of on Carrageenan rat paw edema
(17)
Select 65 of male rats for use, be divided into 6 groups at random: matched group (10ml/kg water); Aspirin group 0.2g/kg; YAOXITONG group 0.11g/kg (clinical daily dose 0.03g/kg 3.5 times); Lumbosacral pain high dose group 1.94g/kg, middle dosage group 1.36g/kg, low dose group 0.78g/kg (be respectively 10 times, 7 times and 4 times of clinical daily dose, down with).Each treated animal ig every day once, continuous five days.Behind the last administration 1h, sc 1% carrageenin solution 0.1ml/ Mus causes inflammation under right back sufficient plantar aponeurosis, with the measurement of special moccasin chi cause scorching before and cause scorching back 0.5h, 1h, 2h, 3h, 4h, 5h and the right ankle of each Mus of 6h joint girth, calculating causes scorching front and back, the difference of ankle joint girth, be swelling degree (mm), as the index of evaluate efficacy.The result: lumbosacral pain 1.94g/kg organizes in 0.5h, 1h, 2h, 3h, 4h, 5h and 6h; 1.36g/kg and 0.78g/kg organizes in 1h, 2h, 3h and 4h; YAOXITONG 0.11g/kg organizes in 1h, 2h, 3h, 4h and 5h, and rat paw edema is all had obvious inhibitory action, with matched group significant difference (table 1) is arranged more all.
Table 1 lumbosacral pain on Carrageenan cause rat paw edema influence (x ± s, n=11)
| Group | Dosage (g/kg) | Cause scorching preceding joint girth (mm) | Different time swollen joint expansibility (mm) after the administration | ||||||
| 0.5h | 1h | 2h | 3h | 4h | 5h | 6h | |||
| Contrast aspirin YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | — 0.20 0.11 0.78 1.36 1.94 | 22.2±0.9 22.5±0.8 22.6±0.7 22.7±0.8 22.6±0.8 23.1±0.7 | 3.3±0.9 1.9±0.7 ** 2.7±0.9 2.9±0.8 2.6±0.7 2.5±0.5 * | 4.5±1.6 1.9±0.6 *** 2.8±0.9 ** 2.7±0.8 ** 2.3±0.5 *** 2.4±0.5 *** | 5.6±1.4 2.5±0.8 *** 3.9±1.5 * 3.5±1.3 *** 3.8±1.2 ** 3.8±1.7 ** | 6.6±1.3 3.7±1.3 *** 5.1±1.0 ** 4.7±1.8 ** 4.9±0.9 ** 5.0±1.0 ** | 7.0±1.3 3.9±1.5 *** 4.9±1.2 *** 5.3±1.6 ** 5.4±1.0 ** 4.7±0.9 *** | 5.6±1.3 3.8±1.2 ** 4.4±1.1 5.2±1.2 5.0±1.2 4.3±1.2 * | 4.7±0.9 3.6±1.2 * 4.1±0.9 3.9±1.4 4.2±1.3 3.0±1.3 ** |
Compare with matched group:
*P＜0.05;
*P＜0.01;
* *P＜0.001; Aspirin group: n=10 only
3.2 to the bullate influence of rat granuloma
Select 56 of male rats for use, ip pentobarbital sodium 30mg/kg anesthesia, the 1cm osculum respectively cuts in strange portion about rat, and 20mg autoclaving cotton balls (soaking oven dry with penicillin 800u and streptomycin 650u mixed liquor 0.2ml) implantation is subcutaneous, immediately skin suture.Be divided into 6 groups at random: matched group (10ml/kg water); Aspirin group 0.2g/kg; YAOXITONG group 0.11g/kg (clinical daily dose 0.03g/kg 3.5 times); Lumbosacral pain high dose group 1.94g/kg, middle dosage group 1.36g/kg, low dose group 0.78g/kg.Began each treated animal ig every day in second day once, continuous 7 days, the cotton balls granulation tissue was taken out in rat execution in the 8th day, 60 ℃ of oven dry, weighing deducts cotton balls weight, calculates the granuloma weight of 100g body weight.The result: lumbosacral pain 1.94g/kg, 1.36g/kg and 0.78g/kg group, YAOXITONG 0.11g/kg group all can obviously suppress the swollen effect of rat granuloma (table 2).
Table 2. lumbosacral pain is to the influence of the swollen weight of rat granuloma (x ± s)
| Group | Dosage (g/kg) | Number of animals (only) | Granuloma dry weight (mg/100g) |
| Contrast aspirin YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | — 0.20 0.11 0.78 1.36 1.94 | 10 9 9 9 9 10 | 42.72±5.94 32.70±7.66 ** 32.58±9.21 * 35.64±6.72 * 32.16±8.75 ** 33.30±7.80 ** |
Compare with matched group:
*P＜0.05;
*P＜0.01
3.3 the influence that Dichlorodiphenyl Acetate induced mice abdominal cavity capillary permeability increases
70 of kunming mices, male and female half and half are divided into 6 groups at random: matched group (20ml/kg water); Aspirin group 0.3g/kg; YAOXITONG group 0.3g/kg (clinical daily dose 0.03g/kg 10 times); Lumbosacral pain high dose group 5.82g/kg, middle dosage group 3.88g/kg, low dose group 1.94g/kg (be respectively 30 times, 20 times and 10 times of clinical daily dose 0.194g/kg, down with).Each treated animal ig every day once, continuous 5 days, behind the last administration 1h, Mus tail iv 1% Azo-Blue solution 10ml/kg, ip 0.7% acetum 0.2ml/ is only immediately, taking off vertebra behind the 20min puts to death, cut off skin of abdomen muscle, divide with the 6ml normal saline and wash the abdominal cavity for several times, with suction pipe sucking-off cleaning mixture, add normal saline after the merging to 10ml, get supernatant after centrifugal and survey absorbance in the 590nm place.The result: lumbosacral pain 5.82g/kg, 3.88g/kg group, YAOXITONG 0.3g/kg group all can obviously suppress acetic acid induced mice abdominal cavity capillary permeability increase effect (table 3).
Table 3. lumbosacral pain is to the influence of mice capillary permeability (x ± s)
| Group | Dosage (g/kg) | Number of animals (only) | The OD value | Suppression ratio (%) |
| Matched group aspirin YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | 0.30 0.30 1.94 3.88 5.82 | 12 12 12 11 11 12 | 0.477±0.110 0.264±0.09 *** 0.335±0.135 * 0.503±0.270 0.304±0.137 ** 0.280±0.116 *** | 44.7 29.8 -5.2 36.3 41.3 |
Compare with matched group:
*P＜0.05;
*P＜0.01;
* *P＜0.001
3.4 the influence of Dichlorodiphenyl Acetate induced mice writhing response
60 of kunming mices, male and female half and half are divided into 6 groups at random: matched group (20ml/kg water); Morphine group 10mg/kg; YAOXITONG group 0.3g/kg (clinical daily dose 0.03g/kg 10 times); Lumbosacral pain high dose group 5.82g/kg, middle dosage group 3.88g/kg, low dose group 1.94g/kg.Each treated animal ig every day once continuous 5 days, behind the last administration 1h, ip 1% acetum 0.2ml/, observes mouse writhing number of times in the 20min.The result: lumbosacral pain 5.82g/kg, 3.88g/kg group, YAOXITONG 0.3g/kg group all can obviously suppress mouse writhing number of times effect (table 4).
The influence of table 4. lumbosacral pain Dichlorodiphenyl Acetate induced mice writhing response (x ± s)
| Group | Dosage (g/kg) | Number of animals (only) | Turn round the body number of times (inferior/20min) | Suppression ratio (%) |
| Matched group morphine YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | — 0.01 0.30 1.94 3.88 5.82 | 10 10 10 10 10 10 | 44.3±9.6 0.0±0.0 24.2±6.2 *** 36.2±12.2 27.2±8.8 *** 23.6±6.7 *** | 100 45.4 18.3 38.6 46.7 |
Compare with matched group:
* *P＜0.001
3.5 influence (hot plate method) to the mice hot plate threshold of pain
Select female kunming mice for use, hot plate temperature is 55 ± 0.5 ℃, and it is pain threshold to occurring licking the metapedes required time of reaction that mice is put into hot plate.60 of the mice of preliminary election pain threshold within 5～20 seconds are divided into 6 groups at random, measure once more and respectively organize normal pain threshold once, get its 2 averages as administration before normal pain threshold.Each treated animal is pressed table 5 dosage ig every day once, continuous 5 days, respectively measures the mice pain threshold once respectively at 60min, 90min and 120min after the last administration.The result: lumbosacral pain 5.82g/kg organizes in 60min, 90min and 120min; 3.88g/kg organize in 90min; 1.94g/kg organize in 60min and 90min; YAOXITONG 0.3g/kg organizes in 60min and 90min all can significantly improve the mice pain threshold, with matched group notable difference (table 5) is arranged relatively.
Table 5. lumbosacral pain to the influence of mice pain threshold (x ± s, n=10)
| Group | Dosage (g/kg) | The preceding threshold of pain of administration (s) | The threshold of pain after the administration (s) | ||
| 60min | 90min | 120min | |||
| Matched group rotundine YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | — 0.045 0.30 1.94 3.88 5.82 | 13.2±1.9 13.6±2.5 13.3±2.0 13.6±1.6 13.0±2.2 12.9±1.4 | 12.7±2.2 17.6±2.2 *** 15.3±1.7 ** 15.5±2.6 * 13.7±1.5 16.0±2.3 ** | 13.0±2.2 19.4±3.4 *** 16.7±3.2 ** 15.5±1.9 * 16.3±1.9 ** 17.4±2.5 *** | 12.9±2.3 17.2±2.3 *** 14.4±2.8 13.8±2.0 13.6±1.2 15.7±2.2 * |
Compare with matched group:
*P＜0.05;
*P＜0.01;
* *P＜0.001
3.6 Dextran is brought out the influence of the acute microcirculation disturbance of rat mesentery (AMD)
Select 59 of Wistar rats for use, be divided into 6 groups at random, press literature method
(19)Operation undergos surgery, rat ip pentobarbital sodium 30mg/kg anesthesia, otch in the capable 2cm of abdomen median line, the rat mesocecum is laid in the lucite perfusion box that fills 37 ℃ of tyrode's solutions of constant temperature, by microcirculation microscope and the microcirculatory variation of little image computer blood processor observed and recorded rat mesentery.With the intravenous injection of 10%Dextran 6ml/kg tongue, cause rat mesentery AMD.Behind the 5min, each treated animal is pressed table 6 dosage respectively through duodenal administration, the variation of 10min, 20min, 30min, 60min rat mesentery specific region thin vein blood flow rate, the open number of blood capillary behind the observation medicine.The thin vein blood flow rate of result: AMD group rat all slows down in the time at the 60min of whole observation period, has reached the peak during 10min, during 60min and 0min still have marked difference (p＜0.01); The open number of blood capillary also significantly reduces when 10min, but recovers substantially when 30min, does not relatively have significant difference (P＞0.05) with 0min.10min behind the duodenal administration, the thin vein blood flow rate of each dosage group of lumbosacral pain and YAOXITONG 0.11g/kg group obviously slows down, during 30min with 0min no significant difference (P＞0.05) relatively, the basic recovery normally; But during 30min, each administration group and AMD group relatively have notable difference.The open number of blood capillary obviously reduces, and both all begin to recover behind 20min, only has the open number of blood capillary 10min behind medicine of 1.94/kg group to begin to recover in each dosage group of lumbosacral pain.Compare with the AMD group: lumbosacral pain 1.94g/kg organizes when 20min, 30min and 60min; 1.36g/kg and 0.78g/kg organizes when 30min and 60min; The thin vein flow velocity of YAOXITONG group when 30min and 60min all obviously accelerated; Lumbosacral pain 1.94g/kg and 1.36g/kg organize when 30min and 60min; The open number average of blood capillary that YAOXITONG 011g/kg organizes when 30min is significantly increased.Above-mentioned experimental result shows, celestial cattle lumbosacral pain granule brings out the acute microcirculation disturbance tool of rat mesentery improve significantly (table 6-1,6-2) to Dextran.
Table 6-1. lumbosacral pain to the influence of the acute microcirculation disturbance of rat mesentery (x ± s, n=10)
| Group | Dosage (g/kg) | Thin vein blood flow rate (um/s) | ||||
| 0min | 10min | 20min | 30min | 60min | ||
| AMD Radix Salviae Miltiorrhizae drop pill YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | — 0.044 0.11 1.94 1.36 0.78 | 216.2±23.32 221.1±38.79 216.6±39.44 232.0±33.48 217.5±30.88 213.6±39.00 | 104.9±52.92 △△△ 149.8±48.84 △△ 120.4±43.28 △△△ 146.2±68.65 △△ 122.8±66.63 △△ 148.3±42.44 △△ | 131.6±29.25 △△△ 188.2±36.12 ** 140.2±45.97 △△△ 184.7±38.41 △△** 148.5±74.33 △ 168.7±48.39 △ | 156.6±25.32 △△△ 214.8±39.56 ** 184.3±31.07 * 210.2±28.58 *** 195.9±34.97 ** 194.5±37.59 * | 181.0±22.47 △△ 226.8±31.61 ** 211.1±77.2 * 227.6±39.92 ** 215.0±29.69 ** 215.7±35.18 * |
Compare with 0min:
△P＜0.05;
△ △P＜0.01;
△ △ △P＜0.001; Compare with the AMD group:
*P＜0.05;
*P＜0.01;
* *P＜0.001; Lumbosacral pain 0.78/kg group: n=9
Table 6-2. lumbosacral pain to the influence of the acute microcirculation disturbance of rat mesentery (x ± s, n=10)
| Group | Dosage (g/kg) | The open number (bar) of blood capillary | ||||
| 0min | 10min | 20min | 30min | 60min | ||
| AMD Radix Salviae Miltiorrhizae drop pill YAOXITONG lumbosacral pain lumbosacral pain lumbosacral pain | — 0.044 0.11 1.95 1.37 0.78 | 16.0±3.89 15.9±3.14 16.7±2.16 15.9±3.84 16.0±4.35 16.3±3.71 | 11.4±2.80 △△ 12.8±2.78 △ 13.3±2.31 △△ 12.2±3.77 △ 12.7±2.06 △ 12.0±1.87 △△ | 11.4±2.37 △△ 13.9±2.28 * 13.3±2.16 △△ 12.7±3.83 12.7±1.77 △ 12.8±1.72 △ | 12.3±2.54 △ 16.5±3.72 ** 14.8±1.87 * 15.7±3.43 * 15.5±3.69 * 14.6±3.09 | 14.4±3.20 18.2±2.86 * 17.6±2.41 * 17.2±2.49 * 18.0±3.06 * 16.3±4.15 |
Compare with 0min:
△P＜0.05;
△ △P＜0.01; Compare with the AMD group:
*P＜0.05;
*P＜001; Lumbosacral pain 0.78g/kg group: n=9
4. experiment conclusion
Pharmacodynamic study result: ig administration: lumbosacral pain 0.78,1.36,1.94g/kg, YAOXITONG 0.11g/kg on Carrageenan causes rat paw edema, rat granuloma swells all the obvious suppression effect; Lumbosacral pain 3.88,5.82g/kg, YAOXITONG 0.3g/kg Dichlorodiphenyl Acetate induced mice abdominal cavity capillary permeability increases, the mouse writhing reaction all has the obvious suppression effect; Lumbosacral pain 1.94,3.88,5.82g/kg, YAOXITONG 0.3g/kg all can obviously improve mice hot plate reaction pain threshold; Lumbosacral pain 0.78,1.36,1.94g/kg, YAOXITONG 0.11g/kg causes that to Dextran rat mesentery AMD all improves significantly.Show that lumbosacral pain has analgesia, antiinflammatory and microcirculation improvement effect.
The specific embodiment
The preparation of granule dosage form
1. take by weighing Herba Epimedii 20g and decoct with water 3 times, add water 200g at every turn, decocted 20 minutes, collecting decoction filters, and filtrate is evaporated to relative density 1.10-1.15. at 80 ℃, 0.08Mpa
2. take by weighing Rhizoma Homalomenae 20g, Cortex Illicii 20g, Radix Achyranthis Bidentatae 10g adds decocting and goes into 3 times, adds water 400g at every turn, the person of frying in shallow oil 1 hour, collecting decoction filters, and filtrate is evaporated to relative density and crosses 1.10-1.15 at 80 ℃, 0.08Mpa.
3. the fluid extract that merges Herba Epimedii and other three kinds of raw materials together continues to be concentrated into relative density 1.28-1.31 under 80 ℃, 0.06Mpa condition, again under 80 ℃, 0.08Mpa condition, and drying under reduced pressure.
4. dry thing is ground into 140 order fine powders, in medicated powder, adds steviosin 5g, add dextrin to 1000g, mix homogeneously, adding 100g concentration again is that 80% ethanol is wetting agent, makes granule, 60 ℃ of dried particles, granulate can packing patent medicine.According to the effective dose of drug use of the present invention, can be distributed into every bag 4 gram.As final purpose is the system medicine for external use, and can add 200ml concentration after with the extract drying and crushing is that 80% ethanol is made tincture.
Measure in force, final gained pharmaceutically active substance is the 17-18% of raw materials used gross weight.In the present embodiment, contain active ingredient in every bag of medicine and be about 0.05 gram.
Therapeutic Method:
Oral: each one bag, three times on the one, boiled water is taken after mixing it with water.
The course of treatment: five days courses of treatment, can cure a general course of treatment.
External: tincture is applied painful area, three to five times on the one.
Claims (3)
1. a medicine for the treatment of lumbosacral pain is characterized in that: made by following parts by weight of traditional Chinese medicines raw material; Herba Epimedii 10-30 part, Rhizoma Homalomenae 10-30 part, Cortex Illicii 10-30 part, Radix Achyranthis Bidentatae 10-15 part; Wherein Herba Epimedii decocts with water 3 times, adds the water of 10 times of weight at every turn, decocts 20 minutes, and collecting decoction filters, and filtrate is evaporated to relative density 1.10-1.15 under 80 ℃, 0.06-0.08Mpa condition; Rhizoma Homalomenae, Cortex Illicii, Radix Achyranthis Bidentatae decoct with water 3 times, add the water of 8 times of weight at every turn, decoct 1 hour, and collecting decoction filters, and filtrate is evaporated to relative density 1.10-1,15 under 80 ℃, 0.06-0.08Mpa condition;
Merging Herba Epimedii and Rhizoma Homalomenae, Cortex Illicii, Radix Achyranthis Bidentatae mix the fluid extract after the decocting and concentrating, under 80 ℃, 0.06-0.08Mpa condition, continue to be concentrated into relative density 1.28-1.31, again under 80 ℃, 0.08Mpa condition, drying under reduced pressure, dry thing is ground into fine powder, in prepared fine powder, add various conventional adjuvant required when preparing different dosage form, make oral agents commonly used or externally used coating agent with the method for Chinese medicinal of routine.
2. according to the medicine of claim 1, it is characterized in that the parts by weight of each raw material consumption are: 20 parts of Herba Epimedii, 20 parts of Rhizoma Homalomenaes, 20 parts of Cortex Illiciis, 10 parts of Radix Achyranthis Bidentataes.
3, a kind of preparation method for the treatment of the medicine of lumbosacral pain,
Raw material is:
Herba Epimedii 10-30 weight portion, Rhizoma Homalomenae 10-30 weight portion, Cortex Illicii 10-30 weight portion, Radix Achyranthis Bidentatae 10-15 weight portion;
The steps include:
(1) earlier the Herba Epimedii of described weight proportion is decocted with water 3 times, add the water of 10 times of weight at every turn, decocted 20 minutes, collecting decoction, filtration, filtrate is evaporated to relative density 1.10-1.15 under 80 ℃, 0.06-0.08Mpa condition;
(2) Rhizoma Homalomenae, Cortex Illicii, the Radix Achyranthis Bidentatae of described weight proportion decocted with water 3 times again, add the water of 8 times of weight at every turn, decocted 1 hour, collecting decoction filters, and filtrate is evaporated to relative density 1.10-1,15 under 80 ℃, 0.06-0.08Mpa condition;
(3) merging Herba Epimedii and Rhizoma Homalomenae, Cortex Illicii, Radix Achyranthis Bidentatae mix the fluid extract after the decocting and concentrating, under 80 ℃, 0.06-0.08Mpa condition, continue to be concentrated into relative density 1.28-1.31, again under 80 ℃, 0.08Mpa condition, drying under reduced pressure, dry thing is ground into fine powder, promptly makes medicament active composition of the present invention;
(4) in prepared fine powder, add various conventional adjuvant required when preparing different dosage form, make oral agents commonly used or externally used coating agent with the method for Chinese medicinal of routine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310109939 CN1258373C (en) | 2003-10-27 | 2003-10-27 | Medicine for treating lumbosacral pain and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310109939 CN1258373C (en) | 2003-10-27 | 2003-10-27 | Medicine for treating lumbosacral pain and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1611253A CN1611253A (en) | 2005-05-04 |
| CN1258373C true CN1258373C (en) | 2006-06-07 |
Family
ID=34758990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310109939 Expired - Lifetime CN1258373C (en) | 2003-10-27 | 2003-10-27 | Medicine for treating lumbosacral pain and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1258373C (en) |
-
2003
- 2003-10-27 CN CN 200310109939 patent/CN1258373C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1611253A (en) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN1278718C (en) | Traditional Chinese medicine compound preparation for preventing and treating intestinal adhesion and preparing method | |
| CN102772712A (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN108619473A (en) | A kind of Chinese medicine fuming-lotion for treating diabete peripheral herve pathology | |
| CN1258373C (en) | Medicine for treating lumbosacral pain and its preparing method | |
| CN1139565A (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1264540C (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN102205109B (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN1927282A (en) | Preparation for treating arthritis and preparation method thereof | |
| CN101099836B (en) | Traditional Chinese medicine composition for treating ischemic apoplexy and preparation process thereof | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN104825852A (en) | Tibetan medicine composition, preparation method and application thereof | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
| CN116251133B (en) | Pharmaceutical composition and traditional Chinese medicine preparation for treating rheumatism and rheumatoid diseases by using sialon bone | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN100335111C (en) | Medicine for rheumatism and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIUZHENG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: TIANYAO SCIENCE AND TECHNOLOGY CO LTD, JILIN Effective date: 20080725 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080725 Address after: No. 2426, Qianjin Street, hi tech Zone, Jilin, Changchun Patentee after: Xiuzheng Pharmaceutical Group Co.,Ltd. Address before: No. 509 Mao Xiang street, hi tech Development Zone, Jilin, Changchun Patentee before: JILIN TIANYAO SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tongyao Pharmaceutical Group Corp. Assignor: Xiuzheng Pharmaceutical Group Co.,Ltd. Contract fulfillment period: 2009.4.20 to 2019.4.20 Contract record no.: 2009220000015 Denomination of invention: Medicine for treating lumbosacral pain and its preparing method Granted publication date: 20060607 License type: Exclusive license Record date: 20090615 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.4.20 TO 2019.4.20; CHANGE OF CONTRACT Name of requester: TONGYAO PHARMACEUTICAL GROUP CO., LTD. Effective date: 20090615 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Tongyao Pharmaceutical Group Corp. Assignor: Xiuzheng Pharmaceutical Group Co.,Ltd. Contract record no.: 2009220000015 Date of cancellation: 20130315 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050504 Assignee: Xiuzheng Pharmaceutical Group Changchun High-new Pharmaceutical Co.,Ltd. Assignor: Xiuzheng Pharmaceutical Group Co.,Ltd. Contract record no.: 2013220000006 Denomination of invention: Medicine for treating lumbosacral pain and its preparing method Granted publication date: 20060607 License type: Exclusive License Record date: 20130321 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060607 |